Healthcare Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1NEUP Neuphoria Therapeutics
1.26 K
 0.11 
 17.04 
 1.86 
2ACOG Alpha Cognition Common
445.52
 0.06 
 3.81 
 0.24 
3VSEE VSee Health,
359.54
(0.02)
 6.06 
(0.11)
4HCA HCA Holdings
293.44
 0.09 
 2.10 
 0.18 
5HURA TuHURA Biosciences
115.07
 0.02 
 8.94 
 0.17 
6DVA DaVita HealthCare Partners
98.96
(0.01)
 2.37 
(0.02)
7AVR Anteris Technologies Global
91.17
 0.05 
 4.40 
 0.21 
8AAPG Ascentage Pharma Group
60.58
 0.10 
 3.25 
 0.33 
9GH Guardant Health
55.67
 0.14 
 5.21 
 0.74 
10LLY Eli Lilly and
52.05
 0.06 
 1.97 
 0.12 
11BSGM BioSig Technologies, Common
36.58
(0.13)
 8.07 
(1.05)
12IDXX IDEXX Laboratories
21.52
 0.02 
 2.07 
 0.05 
13TLX Telix Pharmaceuticals Limited
20.71
 0.10 
 3.36 
 0.34 
14NTRA Natera Inc
17.06
(0.03)
 2.77 
(0.09)
15WAT Waters
12.07
(0.02)
 1.83 
(0.04)
16MDCX Medicus Pharma Ltd
11.95
 0.09 
 8.58 
 0.75 
17WGS GeneDx Holdings Corp
11.15
 0.08 
 8.41 
 0.70 
18GRDN Guardian Pharmacy Services,
9.8
(0.04)
 3.24 
(0.12)
19DWTX Dogwood Therapeutics,
8.6
 0.12 
 51.39 
 6.33 
20SHC Sotera Health Co
8.57
(0.07)
 2.17 
(0.16)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.